| Term 
 | Definition 
 
        | Phosphodiesterase Inhibitor     - such that CAMP does not get degraded  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Phosphodiesterase Inhibitor   - prevents CAMP from being degraded to 5' AMP |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Phosphodiesterase Inhibitor   - which prevents CAMP from degradation to 5' AMP   Tx Impotence  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Phosphodiesterase Inhibitors    - which prevents CGMP from degradation to 5' GMP which can lead to severe vasodilation    TX Impotence  |  | 
        |  | 
        
        | Term 
 
        | Phenobarbital and other barbiturates |  | Definition 
 
        | Stimulate Synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 
        | Cigarette smoke (benzopyrene) |  | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 
        | Dioxin (TCDD) - agent orange |  | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 
        | Polychlorinated biphenyls (PCB's) |  | Definition 
 
        | 
Stimulate the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
INHIBIT the synthesis of hepatic CYP450 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
  
INHIBIT the synthesis of hepatic CYP450   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
  
INHIBIT the synthesis of hepatic CYP450   Peripheral Neuropathy (USMLE)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
  
INHIBIT the synthesis of hepatic CYP450   Stimulate Modulin in GI tract    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
  
INHIBIT the synthesis of hepatic CYP450   |  | 
        |  | 
        
        | Term 
 
        | Furanocoumarin (grape juice) |  | Definition 
 
        | 
  
INHIBIT the synthesis of hepatic CYP450   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Carbonic Anhydrase Inhibitor    Make Urine Basic   Increases the excretion of weak acids by making urine alkaline    Salicylic Acid hyrdrolyzed from apsirin is a weak acid   TX of Glaucoma   Decrease the production of aqueous humor  S/E: headache, dec libido, kidney stones, etc  say no to p.o. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Makes Urine Acidic   Increase the excretion of weak bases   Ex. Amphetamine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SLOW acetylators    hepatic damage and blood dyscrasias |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SLOW acetylators   Relaxes Vascular Smooth Muscle to Lower BP Increase HR via the arterial baroreflexes    INDIRECT    lupus-like syndrome |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SLOW acetylators    lupus-like syndrome  |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cholinergic agonist   Cardiac: (i.v.) causes a rapide and transient decrease in BP (via NO in endothelial cells) and baroreflexly-mediated tachycardia    After TX with Atropine the i.v. injection increase BP and heart rate by stimulating N1 cholinergic receptors at symp ganglia   Eye: cause rapid and complete MIOSIS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Cholinergic agonist (muscarinic receptor agon)   Used as a provocative agent in diagnosis of BRONCHIAL ASTHMA   |  | 
        |  | 
        
        | Term 
 
        | Carbachol (Carbamylcholine) |  | Definition 
 
        |   
Cholinergic agonist at nicotinic and muscarinic receptors   causes MIOSIS   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Cholinergic agonist    given P.O., its the only one with systemic use   TX bowel stasis, paralytic ileus, urinary retention   do not use with pilocarpine or people with COPD, asthma, hyperthryoid, ulcers    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Cholinergic (muscaranic) agonist  HEART: Decrease HR  Direct Action at the SA Node  Tertiary Amine   Degraded by hepatic enzymes not AChase or pseudocholinesterase   TX: Dry mouth and Dry eyes (Sjogren's syndrome) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Cholinergic agonist (muscarinic)   TX: Sjogren's (dry mouth and dry eyes)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | TX of Glaucoma   MOA: Contracts the meridional fibers of the ciliary muscle increasing the IC angle or tone of the trabeculae allowing better flow of aq humor   Can cause fixation of the lens for near vision Persistent miosis causes poor night vision (headache)   Contraindicated: asthma & COPD, peptic ulcer, atrial flutter |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | B-adrenoreceptor antagonists, selective for beta 1    TX Glaucoma and IOP, w/ no effect on visual accomodation or pupillary size , by reducing aqueous humor production.    MOA: Decreases prodcution of aq. humor   Can cause bradycardia     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | B adrenoreceptor antagonist (b1 & b2)   TX Glaucoma and IOP   MOA: decrease aqueus humor    Side Effects: Can cause bronchoconstriction  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Stable analog of PGF (2alpha)   TX Glaucoma and IOP   Increase uveoscleral outflow    more efficacious than unoprostone    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alpha Adrenergic Agonist   Increase normal outflow Cause MYDRIASIS w/ dipivefrin bound to it due to alpha 1 stimulation of radial muscle   TX Glaucoma and IOP   MOA: alpha 1 - enhances outflow of aqueous humor via the normal pathway   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
TX of Glaucoma and IOP   hyrolyzed to epinephrine (alpha 1)    increases normal outflow and cause MYDRIASIS with epinephrine   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
alpha adrenoceptor agonists  selective for alpha 2    TX of Glaucoma and IOP   Decreasing the rate of production of aqueous humor    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
carbonic anhydrase inhibitor    TX of Glaucoma and IOP   decrease the production of aq. humor   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Inhibitors of AChase  (organophosphate cholinesterase inhibitor)   MOA: Lower IOP by increasing the amount of ACH available to contract meridional fibers of the ciliary muscle    TX of Glaucoma and IOP "last resort drug"   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
TX of Glaucoma    Organophosphate AChase Inhibitors   MOA: Lower IOP by increasing the amount of ACh available to contract meridional fibers of the ciliary muscle  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Osmotic Diuretic    TX of ACUTE ATTACK of Angle Closure Glaucoma    Given IV and does not leave ECF   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Carbamate ACHase inhibitors   Tertiary amine - freely enters CNS   MOA: 1. noncompetitive, slowly reversible inhibition of AChase 2. Cause carbamoylation of AChase active site 3. No direct affect at ACh receptors   TX. Alzheimers (improves behavior and cognition) many side effects    excacerbates Parkinson's |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Carbamate ACHase inhibitors    DRUG of choice = more selective for CNS   Decrease apathy, hallucinations, anxiety and behavioral problems   S/E = diarrhea, muscle cramps, fatigue, insomnia, anorexia   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Slowly Reversible Carbamate ACHase inhibitors    Quaternary amine   MOA: Inhibits ACHase which increase ACh at the N2 receptor of NMJ   1. Used to manage (check TX) myasthenia gravis treatment 2. Atony of the GI and GU tracts     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Carbamate ACHase inhibitors    Longer-term p.o dosing used to treat myasthenia gravis too much = cholinergic crisis too little = myasthenic crisis  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Carbamate ACHase inhibitors    quarternary amine     MOA: direct stimulation of cholinergic N2 receptors, extremely short half-life   TX: 1. diagnosis of myasthenia gravis 2. distinguish between "myasthenic" and cholinergic crisis in patients treated with p.o. pyridostigmine     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Carbamate ACHase inhibitors  (irreversible organophosphate inhibitors)   insecticide    Humans are poisoned with this... TX with ATROPINE   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Organophosphate AChase inhibitors   insecticide for lawns and gardens |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Organophosphate AChase inhibitors  insecticide    1. converted to active metabolite by p450 2. causes many accidental deaths |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Irreversible Organophosphate AChase inhibitors  Insecticide   1. used to kill lice 2. safer than parathion 3. used to kill mosquitos |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | TX of Organophosphate Poisoning   quarternary   NOT USE for carbamate insecticides  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists    block peripheral and central muscarinics  * exhibits differential sensitivity to atropine sulfate    * not expressed when the drug is given in normal therapeutic doses   * decrease production of saliva or pulmonary secretions * counteract bradycardia * blocks SE of neostigmine and pyridostigmine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    little effect on HR   causes somnolence, euphoria, amnesia, dreamless sleep TX motion sickness |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    induces MYDRIASIS causing "pupillary block"    tertiary compound   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    MYDRIASIS: short duration of action, needed for thorough examination of retina and optic disk   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary compounds   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary compound   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists   tertiary compounds  GI Disease |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary compound   GI disease: spasticity   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary compounds TX overactive bladder   Direct Antispasmodic effect on detrusor   May cause drowsiness, somnolence, dizziness |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary amine * DO NOT USE IN ELDERLY   TX Overactive bladder    S/e somnolence, dry mouth, blurred vision, and constipation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary amine   Selective M3 muscarinic receptor   less dry mouth than oxybutnin, tolteridine and trospium   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary amine no CNS or CV effects   less dry mouth compared to oxybutynin, tolteridine and trospium |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists    tertiary compound   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscarinic receptor antagonists (quaternary)    part of N-methyl PIG   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary)   quartenary cmpd |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary)   * used to decrease the production of saliva/pulmonary secretions * counteracts bradycardia caused by ocular pressure |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor antagonists (quaternary)     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | nicotinic receptor agonists   1. Adverse effect on plasma lipid profile 2. endothelial cell dysfunction 3. increased platelet aggregation  4. neutrophil activation and aggregation 5. increased transcapillary escape of albumin 6. insulin resistance and hyperinsulinemia 7. cardiac dysrhymias via carbon monoxide |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
nicotinic receptor agonists IV injection causes an initial, single contraction of skeletal muscle followed by a flaccid paralysis    Flaccid paralysis is caused by the constant depolarization of the motor endplate = noncompetitive block    degraded by plasma cholinesterase  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | N-1 receptor antagonis = ganglionic blocking drugs    used to produce controlled hypotension during head and neck injury    can also cause further dilation  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
N-1 receptor antagonis = ganglionic blocking drugs    controls symptoms from autonomic hyperreflexia by preventing the paroxysmal increases in sympathetic activity    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Adrenergic agonists  (selective for alpha 1)   Decrease HR    INDIRECT via baroreflexes   Increase TPR, Increase DBP    SV NOT CHANGED b/c Starling    Vasoconstrictive with local anesthetic or CO and tissue perfusion are normal |  | 
        |  | 
        
        | Term 
 
        | Dopamine   (including receptor preference)   |  | Definition 
 
        |   
D1 > B1 > alpha 1   small dose: dilates renal afferent arterioles (D1), increase RBF, GFR and sodium excretion   middle dose: stimulate both renal (D1)  and myocardial (B1); increase in contractility, SV, CO, RBF, GFR    large dose: begins to stimulate resistance arterioles and venules (A1), increase in TPR and afterload, decrease SV/CO   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Beta 1 > Beta 2   Stimulates B 1 selectively    Blocks Alpha 1   Increase GFR   Arteriolar Dilation (B2): lowers TPR and DBP   Venodilation (B2): decrease Venous Return    No effects on HR at normal doses Causes Tachycardia in excess   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
  
Beta-Adrenergic Agonists    Increase HR by direct stimulation of the SA node  Increase AV conduction in AV block   Increase SV and PP   Decrease in DBP via Beta 2 stimulation   SBP unchanged           |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
B2 >> B1 
Adrenergic Agonists   Relieve bronchoconstriction associated wit hasthma, COPD and bronchitis   Longer lasting than albuterol       |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
B2 >> B1   * relaxes uterine smooth muscle in order to delay parturition * relaxes uterine muslce to help fetus in breech   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
pure alpha 1 receptor stimulation    Cardio effects are the same as NE   Increase SBP and DBP no change in SV (pulse pressure) Decrease HR via carotid baroreflex     Systemic vasoconstrictor   Relieves nasal congestion by constricting blood vessels Produces MYDRIASIS for fundoscopic exam     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
alpha only   nasal decongestant   longer duration of action than phenylephrine      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
  
Adrenergic Agonists    acts at periphery   found in cheese, wine, beer and pickled herring   not therapeutic      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
  
Adrenergic Agonists    d-; d,l-; methylphenidate : BLOCK uptake 1   - used to treat ADD     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
MIXED AGONIST    B1 and B2 (bronchodilation and AV conduction in AV block)    Releases NE which act on alpha and Beta (MYDRIASIS, increased BP and nasal decongestion)   
 net effect: increased BP, HR, CO, AV conduction 
 increased FEV, mydriasis, insomnia     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
(Sudafed) 
Adrenergic Agonists      less CNS excitation, BP, HR increase   Sinus decongestant     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A1 > A2   Alpha-adrenoceptor antagonist   * non-competitive receptor blockade due to alkylation of receptors   S/E: Fainting  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Alpha-adrenoceptor antagonist (both strongly)   used to reverse ischemia and tissue necrosis caused by extravasated dopamine from veins during iv |  | 
        |  | 
        
        | Term 
 
        | prazosin (terazosin, doxazosin) |  | Definition 
 
        |   
Alpha 1 only -adrenoceptor antagonist relieve urinary obstruction    prazosin ( treatment of peripheral vascular disease ie frostbite, vasospasm)  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Alpha 1A-adrenoceptor antagonist   no alpha2   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | beta-adrenoceptor antagonists   alpha -adrenoceptor antagonists  alpha 2 > alpha 1   causes tachycardia, tremor, and slight increase BP lowers BP in hypertensive pts (not helpful in pheochromocytoma pts)   highly lipid soluble  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Alpha 2 > Alpha 1 
Alpha-adrenoceptor antagonist   |  | 
        |  | 
        
        | Term 
 
        | Ergotamine, dihyroergotamine |  | Definition 
 
        |   
Alpha-adrenoceptor antagonist   partial agonists    constricts cerebral blood vessels by acting as a partial alpha agonist    TX - migraine headache -- many s/e |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Beta-adrenoceptor antagonists |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Beta-adrenoceptor antagonists  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Beta-adrenoceptor antagonists    short half-life   cardioselective beta1   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Beta-adrenoceptor antagonists  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sympatholytic drugs   Decrease release of NE from sympathetic neurons --> Reducing TPR --> reducing BP   HR decreased, TPR decreased, DBP decreased balanced vasodilation   TX hypertension in pregnant women and children because its not teratogenic  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sympatholytic Drugs   MAO: 1. destorys storage vesicles for neurotransmitter in central and peripheral neurons 2. NE release is not inhibited    Effects: Balanced Vasodilation Decreased HR, CO is unchanged    S/E: teratogenic, orthostatic hypotension, sexual dysfunction   Chronic decrease in the neuronal release of NE results in up-regulation of a and B receptors -- supersensitivity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Sympatholytic Drugs - adrenergic neuronal blocking drug   * inhibition of NE release from peripheral sympathetic neurons   (Dilation of arterioles) Decrease TPR, BP (Dilation of venules) Decrease in Venous Return Balanced Vasodilation   HR unchanged, CO unchanged     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Alters NE Metabolism   MOA: 1. local anesthesia (blocks Na channels) 2. noncompetitive blockade of uptake 1 (NE accumlates in nerve junction = vasoconstriction) 3. acts centrally to increase peripheral sympathetic flow 4. euphoria and addiction from DA stimulation in nucleus accumbens   Increase BP and HR |  | 
        |  | 
        
        | Term 
 
        | Sodium   What happens when ion conductance is increased?   Decreased ion conductance?  |  | Definition 
 
        | Increase = rapid depolarization   Decrease = no depolarization  |  | 
        |  | 
        
        | Term 
 
        | 
 Potassium    What happens when ion conductance is increased?   Decreased ion conductance?  |  | Definition 
 
        | Increase = rapid hyperpolarization   Decrease = decreased membrane potential membrane |  | 
        |  | 
        
        | Term 
 
        | Chloride    
 What happens when ion conductance is increased?   Decreased ion conductance?  |  | Definition 
 
        | Increase = rapid depolarization   Decrease = decreased membrane potential difference |  | 
        |  | 
        
        | Term 
 
        | Calcium   
 What happens when ion conductance is increased?   Decreased ion conductance?  |  | Definition 
 
        | Increase = slow depolarization   Decrease = no depolarization |  | 
        |  | 
        
        | Term 
 
        | A patient with increase ACh release.    How is ion conductance related?   Where type of receptors are involved and where are they located? |  | Definition 
 
        | Sodium ion conductance increases.    Coupled to N1-cholinergic receptors located in sympathetic and parasympathetic ganglia and N2 cholinergic receptors at the neuromuscular junction.  |  | 
        |  | 
        
        | Term 
 
        | A patient given inhibitory amino acids would be expected to exhibit ______?    Name 2 inhibitory amino acids |  | Definition 
 
        | Increased Chloride Conductance   1. GABA 2. Glycine |  | 
        |  | 
        
        | Term 
 
        | Properties of lipid-solube compounds on transmembrane travel.    Name 3 important ones: |  | Definition 
 
        | They freely cross the cell memrbane and bind to cytoplasmic receptors.    Corticosteroids, Aldosterone, Vitamin D |  | 
        |  | 
        
        | Term 
 
        | Substance that increase Cl- conductance: |  | Definition 
 
        | Barbiturates Volatile Anesthetic gases propofol ETHANOL |  | 
        |  | 
        
        | Term 
 
        | Role of excitatory amino acids on ion conductance.   Name two important ones.  |  | Definition 
 
        | Increase in Sodium and Calcium conductance   1. Glutamate [kainate, AMPA, NMDA receptors] 2. Aspartate |  | 
        |  | 
        
        | Term 
 
        | What is the affect of Serotonin on Sodium conductance via 5-HT receptor? |  | Definition 
 
        | Increases sodium conductance |  | 
        |  | 
        
        | Term 
 
        | What happens during stimulation of Beta-adrenoceptors on G-protein receptors |  | Definition 
 
        | Activates adenyl cyclase -> cAMP -> degraded by PDEases to 5'-AMP   PDEases inhibited by theophylline, caffeine and papaverine |  | 
        |  | 
        
        | Term 
 
        | Describe intiation/termination of drug acction |  | Definition 
 
        | SLOW -- because the steps of protein synthesis must be changed |  | 
        |  | 
        
        | Term 
 
        | The mode of action of Thyroxine, estrogen and androgens |  | Definition 
 
        | Alter gene transcription after binding to recepors in the nucleus or on DNA |  | 
        |  | 
        
        | Term 
 
        | Biological affect of reversible phosphorylation |  | Definition 
 
        | Allows amplification of the signal and persistence of the biological effect after receptors are non longer stimulated by an agonist |  | 
        |  | 
        
        | Term 
 
        | What secondary messengers are involved control smooth muscle control? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | The increase of intracellular Calcium signals what in cells? |  | Definition 
 
        | Enhanced cellular function. |  | 
        |  | 
        
        | Term 
 
        | If cAMP increases, what will happen to free intracellular Calcium? |  | Definition 
 
        | Cannot say. It may have no effect on free intracellular Calcium    Ex. Beta2 adrenoceptors causes relaxation of vascular smooth muscle  |  | 
        |  | 
        
        | Term 
 
        | What is the loading dose and how is it determined? |  | Definition 
 
        | Loading dose is administered in order to achieve a plasma drug concentration within the therapeutic window quickly. 
 = Concentration in plasma x Dist. Vol
 ------------------------------------
 Bioavailability (F, no units)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Vascular endothelial cells - constitutive Marcophages, neutrophils, smooth muscle cells - induced by cytokines |  | 
        |  | 
        
        | Term 
 
        | Physiologic Actions of NO |  | Definition 
 
        | Vasodilation Decrease BP inhibits platelet adhesion and aggregation inhibts neutrophil adhesion to vascular endo neurotransmitter in CNS Erection  |  | 
        |  | 
        
        | Term 
 
        | Nitrous Oxide action on cell |  | Definition 
 
        | Directly activates cytoplasmic Guanyl cyclase -> increased intracellular cGMP -> MLC phosphatase activated and dephosphorylates -> relaxes VSM  = contraction |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Increased intracellular cGMP and vasodilation because it inhibits PDEase |  | 
        |  | 
        
        | Term 
 
        | Arrange receptors in the time needed to turn on/off from fastest to slowest |  | Definition 
 
        | ION Channel < Enzyme < Transcription of mRNA (protein) |  | 
        |  | 
        
        | Term 
 
        | Formula and Definition for affinity |  | Definition 
 
        |  = 1/Kd = 1/ (k2/k1)   ability of drug to form a stable complex with receptor     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Biological effectiveness of a drug receptor complex    - quantal response when one drug molecules occupies one receptor  |  | 
        |  | 
        
        | Term 
 
        | Biggest difference between competitive and non-competitive inhibitors |  | Definition 
 
        | Competitive = reversible Non-competitive = irrversible   for non competive -- tissue must synthesize new receptors before the reponse to the agonist can be restored completely |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Feature pharmacokinetic tolerance |  | Definition 
 
        | Drug metabolism is increased so plasma concentration of drug falls since dosing remains constant |  | 
        |  | 
        
        | Term 
 
        | Feature of Pharmacodynamic tolerance |  | Definition 
 
        | the tissue response to the drug dimishes  a. decrease in receptor number b. decrease in efficiency of signal transduction example: ethanol |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Development of tolerance to one drug as a result of prior exposure to another drug. |  | 
        |  | 
        
        | Term 
 
        | HOw to read Scatchard plot |  | Definition 
 
        | If intercept of x-axis moves right = increase receptor   If interecept of x-axis moves left = decrease receptor   Steeper slope = greater the affinitu |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Efficacy - max clinical effect (which one does the most)   Potency - the dose of drug required to achieve a particular affect  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | LD (50)/ ED (50)   Death / Anesthesia of 50% of subjects |  | 
        |  | 
        
        | Term 
 
        | Pharmacodynamics vs. Pharmacokinetics |  | Definition 
 
        | PDynamics -What the drug does to your body   PKinetics - What your body does to the drug |  | 
        |  | 
        
        | Term 
 
        | Enteral routes of drug administration and speed |  | Definition 
 
        | Buccal - rapid, high FIRST PASS Per os - absorption is low Rectal - decreased FIRST PASS |  | 
        |  | 
        
        | Term 
 
        | Parenteral Drug Administration and speed |  | Definition 
 
        | IV - rapid IM - rapid, good for depot SQ - rapid for aqueous preps Intrathecal - high local concentration |  | 
        |  | 
        
        | Term 
 
        | Where are basic drugs best absorbed? |  | Definition 
 
        | Small Bowel because the relative absence of hydrogen ions |  | 
        |  | 
        
        | Term 
 
        | Where are acidic drugs are best absorbed? |  | Definition 
 
        | In the STomach because the superabundance of hyrogen ions |  | 
        |  | 
        
        | Term 
 
        | Determine Lipid Solubility |  | Definition 
 
        | Oil/Water coefficient   10 is very soluble and will easily pass through membranes    0.1 indicates that the drug is poorly lipid-soluble |  | 
        |  | 
        
        | Term 
 
        | Where's is most drug absorbed regardless of pKa |  | Definition 
 
        | small intestine because of its large surface area |  | 
        |  | 
        
        | Term 
 
        | Hepatic Biotransformation |  | Definition 
 
        | makes drugs more water soluble so that they can be excreted by the kidney |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Drug is metabolized by the liver soon after absorption and keeps it out of systemic circulation |  | 
        |  | 
        
        | Term 
 
        | Two phase Biotransformation |  | Definition 
 
        | Phase 1 - changes the chemical structure of the drug by oxidation, hydroxylation, deamination and dealkylation    Phase 2 - involve the conjugation of drugs to endogenous compounds |  | 
        |  | 
        
        | Term 
 
        | A major cause of drug toxicity______ |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | By manipulating the urinary PH we can keep ions in the urine   - acidic things are trapped in the urine by an acidic pH - basic things are trapped/excreted in urine by alkaline pH |  | 
        |  | 
        
        | Term 
 
        | Free drug travel in interstitial fluid and cell membranes |  | Definition 
 
        | Free drug travels easily through capillaries to interstitial fluid   Free drug has difficulty passing through cell membranes unless it is very lipid or actively transported  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | (F) Fraction of drug dose that reaches systemic circulation as unchanaged drug following extravascular dosing
 |  | 
        |  | 
        
        | Term 
 
        | If "apparent volume" or distribution or Vd is greater than 0.6 -- what does that indicate? |  | Definition 
 
        | That drug is being retained in the tissues. |  | 
        |  | 
        
        | Term 
 
        | Describe Zero-order kinetics |  | Definition 
 
        | A CONSTANT amount of drug is eliminated per unit of time |  | 
        |  | 
        
        | Term 
 
        | Describe drug elimination follows first-order kinetics. |  | Definition 
 
        | A constant faction of drug is eliminated per unit of time. ex. 10% drug/h |  | 
        |  | 
        
        | Term 
 
        | Why is the body able to eliminate a constant fraction of drug per unit of time. |  | Definition 
 
        | First order kinetics so there is never saturation of drug. |  | 
        |  | 
        
        | Term 
 
        | Elimination rate is synonomous with what |  | Definition 
 
        | fractional rate constant (First order kinetics) |  | 
        |  | 
        
        | Term 
 
        | Formula for elimination rate constant (K) |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Plasma Concentration at steady state occurs after 4 half-lifes. |  | 
        |  | 
        
        | Term 
 
        | Hepatic Clearance formula |  | Definition 
 
        | Cl = rate out/ Concentration in plasma |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | = ((Concentration in urine x Uvol/t) -----------------------------
 Concentration of drug in plasma
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 0-120 = drug filtered and partially abs 120 = drug filtered not absorbed (creatinine and inulin)
 120-600 = drug secreted and partially reabs
 600 = drug secreted and not reabsorbed (PAH)
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | = total amt of drug in the body x k |  | 
        |  | 
        
        | Term 
 
        | After iv administration the plasma concentration of drug drops quickly then declines steadily. What accounts for this early disappearance of drug? |  | Definition 
 
        | It is NOT due to the elimination of drug from the body. |  | 
        |  | 
        
        | Term 
 
        | How does administration of a loading dose affect the time needed to reach plasma concentration steady state? |  | Definition 
 
        | Loading dose does not shorten the time that it takes to reach Cp steady state. |  | 
        |  | 
        
        | Term 
 
        | How do Cp steady state and Cp from a single p.o. dose compare? |  | Definition 
 
        | Cp steady state is always greater than single dose |  | 
        |  | 
        
        | Term 
 
        | What happens to half-life of a drug when renal excretion is decreased due to injury? |  | Definition 
 
        | The half-life is increased. |  | 
        |  | 
        
        | Term 
 
        | Main sign of hepatic dysfunction. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the relationship between in the Cp(ss) and the dosing rate |  | Definition 
 
        | They are proportional: increase in one is an increase in the other |  | 
        |  | 
        
        | Term 
 
        | Pulse Pressure (calc & determining factors)
 |  | Definition 
 
        | = Systolic - diastolic * determined by SV and Arterial Compliance
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | function of the aorta and large arteries that result in wall stretch to accomodate extra volumes of blood - gives rise to the peripheral pulse (radial etc)
 - generated by LV systole
 |  | 
        |  | 
        
        | Term 
 
        | Describe laminar flow (blood) |  | Definition 
 
        | RBC's flowing closer to the vessel wall have a slower velocity due to bumping and resistance |  | 
        |  | 
        
        | Term 
 
        | Determinant of Diastolic Blood Pressure (DBP) |  | Definition 
 
        | TPR in 4th and 5th order arterioles - controlled by sympathetic nerve activity
 |  | 
        |  | 
        
        | Term 
 
        | Systolic blood pressure (SBP) determinants |  | Definition 
 
        | a. SV b. arterial compliance
 c. DBP
 |  | 
        |  | 
        
        | Term 
 
        | Synonyms for Venous Return |  | Definition 
 
        | PRELOAD LV-EDP
 LV-EDV
 R atrial pressure
 cardiac filling pressure
 pulmonary capillary wedge pressure
 venous capacitance
 |  | 
        |  | 
        
        | Term 
 
        | Determinants of Venous Return (aka preload/LV-EDP) |  | Definition 
 
        | Blood volume distribution of the blood volume
 venous capacitance
 - atrial contractility
 |  | 
        |  | 
        
        | Term 
 
        | Relationship of HR and CO in adults |  | Definition 
 
        | HR is only a minor determinant, the greater influence is venous return |  | 
        |  | 
        
        | Term 
 
        | Relationship of CO and HR in children |  | Definition 
 
        | Increase in HR will increase CO b/c LV is so small and fills quickly |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | "The heart pumps what it gets" - increase venous return = incrase LV wall pressure in diastole
 - increased contractility
 - increase venous return
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | is TPR such arterial constriction = increased afterload
 |  | 
        |  | 
        
        | Term 
 
        | Stroke Volume determinants |  | Definition 
 
        | a. preload b. cardiac contractility
 c. afterload (negatively related)
 |  | 
        |  | 
        
        | Term 
 
        | Afferent input from carotid sinus constantly _______________ |  | Definition 
 
        | inhibits efferent sympathetic outflow and stimulates efferent vagal outflow |  | 
        |  | 
        
        | Term 
 
        | Describe vagal and sympathetic nerve activity at increased BP |  | Definition 
 
        | * decreased sympathetic nerve activity * increased vagal activity
 |  | 
        |  | 
        
        | Term 
 
        | Decrease in afferent nerve activity from the carotid sinus causes what increase? what receptors are stimualted?
 |  | Definition 
 
        | a disinhibition of efferent sympathetic activity * increase in Beta-1 = increased contractility
 * Alpha-1 = arterial (DBP) and venous  constriction (venous return and CO)
 |  | 
        |  | 
        
        | Term 
 
        | Increase in vagal nerve activity causes |  | Definition 
 
        | 1. decrease in HR and AV conduction 2. DIRECT Suppression of atrial contractility
 3. slight decrease in ventricular contractility due to NE inhibition from sympathetic fibers
 |  | 
        |  | 
        
        | Term 
 
        | Where is efferent sympathetic nerve activity generated |  | Definition 
 
        | RVLM Rostral ventrolateral medulla
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Increase in intrathoracic pressure causes baroreceptor to results in increase vagal stimulation leading to great drop in BP |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Symp and Parasymp ganglia   Adrenal Medulla  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cholinergic    Motor end plate of skeletal muscle  |  | 
        |  | 
        
        | Term 
 
        | Location of Muscarinic Receptors |  | Definition 
 
        | Smooth muscle (bladder, intestine, lungs, heart)   Sweat glands   Prejunctional sites of on symp & parasymp neurons   Surface of endothelial cells  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ALPHA-1 Adrenergic:    Contraction = mydriasis     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cholinergic (muscarinic)     Contraction = MIOSIS (decrease in size) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cholinergic (muscarinic)   Contraction = near vision  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | prevents ACh synthesis by blocking choline uptake |  | 
        |  | 
        
        | Term 
 
        | Inhibitors of ACh release |  | Definition 
 
        | hemicholinium   ACh - on its own M2 receptors NE - Alpha 2 on heteroreceptors Opiates - inhibts in GI tract |  | 
        |  | 
        
        | Term 
 
        | What amplifies ACh release in GI Tract? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | MOA: binds to surface protein and transported into cholinergic neurons; protease hydrolyzes protein involved in synaptic storage and exocytotic release of ACh   3. Cholinergic neurotransmission ceases in the nerves which supply the NMJ     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Causes: spastic paralysis * acts within the spinal cord preventing release of inhibitory neurotransmitter  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | causes the excess release of ACH by binding to neurexins in plasma membrane |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | enzyme that chews up acetylcholine   localized: neuronal membranes, NMJ, RBC's   Recovery time: 2-3 months |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | preferred substrates: succinylcholine  procaine   localization: plasma, liver, brain, GI smooth muscle   Recovery: 2 weeks |  | 
        |  | 
        
        | Term 
 
        | Name and describe the two routes of aqueous humor circulation in the eye |  | Definition 
 
        | Pressure Pathway = flow through anterior part of lens --> anterior chamber --> exit Canal of Schlemm (IC angle) --> trabeculae      Uveoscleral = flow into spaces within the ciliary muscle and tissue surrouding sclera (5-25% of normal outflow) |  | 
        |  | 
        
        | Term 
 
        | Intraocular Pressure (define & utility as indicator) |  | Definition 
 
        | Pressure measured on the anterior chamber of the eye   clinical indicator for glaucoma  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | narrowing of the IC angle inhibiting outflow   Cause: MYDRIASIS (which can be drug induced by cyclopentolate)   Symptoms: blurred vision, pain, redness, sweating, nausea, vomiting      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | (95% of patients)    flow of aqueous humor through Canal of Schlemm is impeded due to poor tone or alignment of trabeculae        |  | 
        |  | 
        
        | Term 
 
        | Drugs classes necessary to treat IOP (name the drugs in each class) |  | Definition 
 
        | 3 drugs that do the following:   1. Decreases Outflow normal path * Beta adrenoreceptor antagonist * Carbonic anhydrase inhibitors * alpha adrenoceptor agonists    2. Increase Outflow normal path * PGF (2 alpha) analogs   3. Increase Outflow the Uveoscleral path * alpha adrenoceptor agonists * pilocarpin, isofluophate |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Selective alpha 2 adrenoceptor agonists   Decrease the rate of production of aq. humor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Stable analog of PGF (2alpha)   increase uveoscleral outflow   not as good a latanoprost  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Immunosupressant drug using with pyridostigmine for long-term p.o dosing to treat myasthenia gravis |  | 
        |  | 
        
        | Term 
 
        | Clues for insecticide poisoning affecting muscarinic receptors |  | Definition 
 
        | Miosis, bradycardia, cough, abdominal cramps, sweating and salivation, urinary frequency |  | 
        |  | 
        
        | Term 
 
        | Clues of insecticide affecting nicotini manifestations |  | Definition 
 
        | msk - weakness, cramping   symp ganglia - tachycardia, hypertension |  | 
        |  | 
        
        | Term 
 
        | TX of Organophosphate Poisoning |  | Definition 
 
        | Atropine sulfate (tertiary) - block peripheral and central muscarinics   Praidoxime (quartenary) - regenerates enzyme in periphery |  | 
        |  | 
        
        | Term 
 
        | TX of Carbamate insecticides (carbaryl) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Metabolic effects of IV infusion of EPI and NE during excercise or hypoGlycemia 
 Glucose (plasma) Insulin release FFA (plasma) Lactic A (plasma) Oxygen consump K (plasma)  |  | Definition 
 
        |                                     EPI                   NE 
 Glucose (plasma)   B2     ++                   0/+ Insulin release       A2     -                      -  FFA (plasma)         B1     ++                   0/+ Lactic A (plasma)    B2    ++                   0/+ Oxygen consump            ++                   0/+ K (plasma)            B2     ++                   0/+ |  | 
        |  | 
        
        | Term 
 
        | CNS effects of EPI and NE during excercise   Anxiety Respiration Tremor |  | Definition 
 
        |                             EPI                       NE Anxiety                 ++                        0/+ Respiration            +                          + Tremor                  +                          +/0 |  | 
        |  | 
        
        | Term 
 
        | Selectivity of EPI and NE |  | Definition 
 
        | EPI = Beta 2 (arterial msk)> Beta 1 > alpha   NE = alpha (arterial GI & kid.) > beta1 > beta 2 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | small iv dose: Increase vasodilation (Beta 2) Decrease in TPR and DBP Increase in SV, SBP, contractility   Large iv dose: Vasoconstriction (alpha) Increase TPR and DBP Increase in SV, SBP, contractility   * blood decreases in kidney, GI tract and skin |  | 
        |  | 
        
        | Term 
 
        | Epinephrine (lung, local, anaphylactic use) |  | Definition 
 
        | alpha and beta    bronchodilator in astma and COPD patients   Vasoconstrictive w/ local anesthetic    DOC for TX anaphylactice reactions (reverse bronchoconstriction and laryngeal edema)   DOC for releaving priapism (alpha receptor stim)   * though may damage kidney |  | 
        |  | 
        
        | Term 
 
        | Stroke Volume: Normal vs. Myocardial Infarction (increased preload, contractility, afterload) |  | Definition 
 
        |                                  normal heart               MI increase preload           inc                          dec    increased contractility    inc                         inc   increased afterload       n.c.                         DEC |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | releases nitric oxide which dilates both arterioles and venules    can be given by iv infusion during MI along with dobutamine |  | 
        |  | 
        
        | Term 
 
        | Dobutamine advantages over dopamine in tx of MI |  | Definition 
 
        | 1. does not increase DBP (afterload) is less likely to cause tachycardia causes venodilation which decreases venous return (preload), so cardiac filling pressure is decreased  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Epinephrine causes increase in BP with alpha and b2 receptor stimulation   if alpha antagonist is used (phenoxy, phentolmine, prazosin, tamsulosin, labetalol, yohimbine) then it depresses the BP even more than the antagonist   However if you use a non-selective beta antagonist then give epi -- the spike in BP is greater  |  | 
        |  | 
        
        | Term 
 
        | Hypertensive patient, normal cardiac function, alph receptor blocker PRAZOSIN   Effect on TPR, BP, Venous Capacitance, HR, dp/dt, CO |  | Definition 
 
        | decrease TPR decrease BP Increase VC balanced dilation so no change in the following: HR, Contractility, CO |  | 
        |  | 
        
        | Term 
 
        | How treat prostatic hypertrophy? |  | Definition 
 
        | Doxazosin Terazosin Tamsulosin |  | 
        |  | 
        
        | Term 
 
        | Treatment of Erectile Dysfunction |  | Definition 
 
        | Phentolamine Papaverine Alprostadil Sildenafil |  | 
        |  | 
        
        | Term 
 
        | Side effects of alpha antagonists (alpha blockers) |  | Definition 
 
        | hypotension angina failure to ejaculate miosis nasal congestion abdominal cramps retention of water and salt  |  | 
        |  | 
        
        | Term 
 
        | Name the Beta-blockers for the heart  & selectivity |  | Definition 
 
        | BAM   Betaxolol Atenolo Metoprolol 
 B1 selective   Propranolol Timolol 
 non-selective    Esmolol - short half life |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | HR decrease Prevent Tachycardia caused by excercise, stress   also decrease conduction, AV, Ventricles, dp/dt, CO, Coronary Blood flow   BP is decreased initial reduction in CO |  | 
        |  | 
        
        | Term 
 
        | Beta blockers on the kidney |  | Definition 
 
        | Plasma renin and angiotenin II fall decline in BP Salt and Water retention |  | 
        |  | 
        
        | Term 
 
        | Beta Block effect on lung |  | Definition 
 
        | Increased Airway resistance decrease FEV1   BAM has the least decrease in FEV while propranolol and timolol have the greatest decrease  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Reduce blood flow   pts. compain of cold hands |  | 
        |  | 
        
        | Term 
 
        | Beta-blocker effect on the eye |  | Definition 
 
        | Reduce IOP by decreasing production of aq. humor |  | 
        |  | 
        
        | Term 
 
        | Beta-blocker on metabolism |  | Definition 
 
        | blocks the increase FFA (plasma) cause by smp stimulation of B1 in fat   Blocks B2 glycogenolysis in liver and skeletal muslce  |  | 
        |  | 
        
        | Term 
 
        | Therapeutic uses of Beta blockers |  | Definition 
 
        | Cardiac dysrhytmias (especially catecholamine induced) especially in MI pts (decrease chance of death)   Heart failure (diastolic dysfunction - tx with carvedilol or metoprolol)   Hyperthyroidism (block trmor, tachycardia)   Pheochromocytoma, Glaucoma, essential tremor, mirgraines, portal hypertension (propranolol) |  | 
        |  | 
        
        | Term 
 
        | Adverse effects of Beta blockers |  | Definition 
 
        | Depressed mycoardial contractility Bradycardia Up-regulation of B-adrenoceptors due to withdrawl of propranolo Asthma Diabetes (mask warning signs except sweating) Digital Blood Flow decrease Excercise Intolerance  |  | 
        |  | 
        
        | Term 
 
        | Toxicity associated with Cocaine use |  | Definition 
 
        | 1. Cardia dysrhythmias 2. MI 3. Chest pain 4. Pulmonary Edema 5. CVA - subarachnoid hemorrhage 6. Necrosis of nasal septum 7. Seizure 8. Resp. Disease 9. Sudden death |  | 
        |  | 
        
        | Term 
 
        | What drugs are used to determine refractive error? |  | Definition 
 
        | Scopolamine, atropine, or cyclopentolate   MYDRIASIS and cycloplegia |  | 
        |  | 
        
        | Term 
 
        | How do you treat anterior uveitis and choroiditis |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the treatment for diarrhea |  | Definition 
 
        | Diphenoxylate (opiate) inhibits GI motility   +   Atropine |  | 
        |  | 
        
        | Term 
 
        | Drugs to treat Overactive Bladder |  | Definition 
 
        |   STOp the Darn Tinkling    Oxybutynin   Tolterodine   Trospium   Solifenacin   Darifenacin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tioptropium and Ipratropium |  | 
        |  | 
        
        | Term 
 
        | Compounds the block central muscarinic receptors |  | Definition 
 
        | BBATS in the belfry     Benxtropine Biperiden Atropine Trihexyphenidyl   |  | 
        |  | 
        
        | Term 
 
        | Describe Atropine Toxicity |  | Definition 
 
        | Red as a beet (cutaneous dilation)   Hot as a pistol (hot skin)   Mad as a hatter (delusions)   Dry as a Desert (inhibit salivation)   CNS - nervous, excitation, confusion, hypertension, etc   PNS - dry mouth, thirst, dilated pupils, tachycardia, photophobia |  | 
        |  | 
        
        | Term 
 
        | N1 Receptor Antagonists describe MOA |  | Definition 
 
        | Competitive bloackade of N1 cholinergic receptors in autonomic ganglia prevents all symp/parasymp nerve activity from reaching the effector organs |  | 
        |  | 
        
        | Term 
 
        | Blockade of Symp Ganglia Cause: |  | Definition 
 
        | Decrease TPR decrease venodilation decrease contractility decreased cardiac output hypotension decreased sweating impotence |  | 
        |  | 
        
        | Term 
 
        | Blockade of Parasympathetic Ganglia |  | Definition 
 
        | Tachycardia Mydriasis and cycloplegia decreased salivation & lacrimation decreased GI secretion, motility and tone decreased gastric acid secretion decrease release of pancreatic enzymes and bile constipation and urinary retention impotence (no erection) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Chewing gum Transdermal Nasal Spray |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | perscription antidepressant drug taken p.o.      can cause seizure |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | partial agonist at central alpha and beta nicotinic receptors whose effects mimic tobacco   * causes the release of dopamine  |  | 
        |  | 
        
        | Term 
 
        | Atropine is given as a treatment for ______ |  | Definition 
 
        | SLUDGE    Salivation Lacrimation Urination Diaphoresis GI motility Emesis  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | X (loading dose) = ((Cp x Vd)/F) |  | 
        |  | 
        
        | Term 
 
        | What comprises the uveal tract (uveoscleral route) |  | Definition 
 
        | Iris, ciliary body, ciliary muscle, choroid |  | 
        |  | 
        
        | Term 
 
        | TX of Open-Angle Glaucoma |  | Definition 
 
        | 1. Muscarinic receptor: Pilocarpine - allow flow   Alpha agonist - Epi, Apraclonidine & Brimonidine (alpha 2 selective), Dipivefrin   Beta antagonist - betaxolol, timolol    Carbonic Anhydrase inhibitor - acetazolamide, dorzolamide   2. Inhibitors of AChase - Isoflurophate and echothiophate |  | 
        |  | 
        
        | Term 
 
        | TX of acute attack of angle closure glaucoma |  | Definition 
 
        | Mannitol - given iv causes cellular deydration      |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DTP   Tacrine   Donepezil   Physostigmine |  | 
        |  | 
        
        | Term 
 
        | Quartenary Cholinomimetic Drugs |  | Definition 
 
        | Neostigmine    Pyridostigmine   Edrophonium |  | 
        |  | 
        
        | Term 
 
        | Irreversible Inhibitors of Achase |  | Definition 
 
        | organophosphate    DIMPLE   Dimpylate Isoflurophate Malathion Parathion L Echothiophate |  | 
        |  | 
        
        | Term 
 
        | Muscarinic Antagonists: Quartenary Compounds |  | Definition 
 
        | N methyl PIG   N-methylatropine N-methylhomatropine methscopolamine propantheline ipratropium glycopyrrolate   TT Trospium tiotropium |  | 
        |  | 
        
        | Term 
 
        | Muscarinic Antagonist Quartenary (RAP) |  | Definition 
 
        | Atro - Sco - Ho - Cy Tropic - Benz Tri Bi Di hyo- Oxy To So Da Di  |  | 
        |  |